Palvella Therapeutics, Inc. (PVLA) 10-Year Financial Performance & Capital Metrics

PVLA • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutPalvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.Show more

Revenue $0
EBITDA -$13M -170.2%
Net Income -$17M -193.3%
EPS (Diluted) -7.83 -153.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -59.37%
ROIC -
Debt/Equity -
Interest Coverage -3.26

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 96 (top 4%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 75.6% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-49.48%

EPS CAGR

10Y-

5Y-

3Y-

TTM63.72%

ROCE

10Y Avg-71.36%

5Y Avg-71.36%

3Y Avg-86.7%

Latest-34.64%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	29.32M	31.42M	25.9M	0	0
Revenue Growth %	-	0.07%	-0.18%	-1%	-
Cost of Goods Sold+	0	2.37M	2.78M	0	0
COGS % of Revenue	-	0.08%	0.11%	-	-
Gross Profit+	29.32M	29.05M	23.12M	0	0
Gross Margin %	1%	0.92%	0.89%	-	-
Gross Profit Growth %	-	-0.01%	-0.2%	-1%	-
Operating Expenses+	61.12M	80.88M	66.6M	11.87M	14.1M
OpEx % of Revenue	2.08%	2.57%	2.57%	-	-
Selling, General & Admin	16.9M	16.68M	16.38M	3.08M	5.94M
SG&A % of Revenue	0.58%	0.53%	0.63%	-	-
Research & Development	44.22M	64.2M	50.21M	8.79M	8.15M
R&D % of Revenue	1.51%	2.04%	1.94%	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-33.92M	-51.83M	-43.47M	-11.87M	-14.1M
Operating Margin %	-1.16%	-1.65%	-1.68%	-	-
Operating Income Growth %	-	-0.53%	0.16%	0.73%	-0.19%
EBITDA+	-31.79M	-49.46M	-40.69M	18.69M	-13.12M
EBITDA Margin %	-1.08%	-1.57%	-1.57%	-	-
EBITDA Growth %	-	-0.56%	0.18%	1.46%	-1.7%
D&A (Non-Cash Add-back)	2.13M	2.37M	2.78M	0	0
EBIT	-37.07M	-45.74M	-33.28M	18.69M	-13.12M
Net Interest Income+	511K	4K	721K	6.26M	-4.32M
Interest Income	511K	4K	721K	6.26M	0
Interest Expense	0	0	0	0	4.32M
Other Income/Expense	-3.15M	6.09M	10.2M	30.56M	-3.34M
Pretax Income+	-37.07M	-45.74M	-33.28M	18.69M	-17.43M
Pretax Margin %	-1.26%	-1.46%	-1.28%	-	-
Income Tax+	164K	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-37.23M	-45.74M	-33.28M	18.69M	-17.43M
Net Margin %	-1.27%	-1.46%	-1.28%	-	-
Net Income Growth %	-	-0.23%	0.27%	1.56%	-1.93%
Net Income (Continuing)	-37.23M	-45.74M	-33.28M	18.69M	-17.43M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-54.67	-56.69	-29.61	14.74	-7.83
EPS Growth %	-	-0.04%	0.48%	1.5%	-1.53%
EPS (Basic)	-54.67	-56.69	-29.61	14.74	-7.83
Diluted Shares Outstanding	681.01K	806.84K	930.35K	1.27M	2.23M
Basic Shares Outstanding	681.01K	806.84K	930.35K	1.27M	2.23M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	75.72M	127.63M	16.52M	7.55M	88.23M
Cash & Short-Term Investments	70.44M	117.76M	16.05M	7.35M	83.6M
Cash Only	70.44M	117.76M	16.05M	7.35M	83.6M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	1.71M	3.31M	0	0	2.34M
Days Sales Outstanding	21.24	38.49	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	3.58M	6.55M	471K	198K	2.3M
Total Non-Current Assets+	29.29M	25.93M	0	0	0
Property, Plant & Equipment	25.98M	23.03M	0	0	0
Fixed Asset Turnover	1.13x	1.36x	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	3.31M	2.9M	0	0	0
Total Assets+	105.01M	153.56M	16.52M	7.55M	88.23M
Asset Turnover	0.28x	0.20x	1.57x	-	-
Asset Growth %	-	0.46%	-0.89%	-0.54%	10.69%
Total Current Liabilities+	22.14M	50.56M	5.78M	2.36M	12.04M
Accounts Payable	1.79M	8.61M	3.18M	936K	4.59M
Days Payables Outstanding	-	1.33K	417.65	-	-
Short-Term Debt	1.03M	1.05M	0	0	0
Deferred Revenue (Current)	1000K	1000K	0	0	0
Other Current Liabilities	3.94M	12.21M	921K	344K	6.24M
Current Ratio	3.42x	2.52x	2.86x	3.20x	7.33x
Quick Ratio	3.42x	2.52x	2.86x	3.20x	7.33x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	51.84M	52.24M	33.92M	9.07M	13.59M
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	15.93M	13.84M	0	0	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	6K	0	33.92M	9.07M	13.59M
Total Liabilities	73.98M	102.81M	39.7M	11.43M	25.63M
Total Debt+	16.96M	14.89M	0	0	0
Net Debt	-53.47M	-102.87M	-16.05M	-7.35M	-83.6M
Debt / Equity	0.55x	0.29x	-	-	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-0.39x	-
Interest Coverage	-	-	-	-	-3.26x
Total Equity+	31.03M	50.76M	-23.17M	-3.88M	62.61M
Equity Growth %	-	0.64%	-1.46%	0.83%	17.14%
Book Value per Share	45.56	62.91	-24.91	-3.06	28.13
Total Shareholders' Equity	31.03M	50.76M	-23.17M	-3.88M	62.61M
Common Stock	56K	72K	0	0	11K
Retained Earnings	-211.41M	-257.14M	-94.99M	-76.3M	-93.73M
Treasury Stock	0	0	0	0	0
Accumulated OCI	-295K	829K	0	0	3K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-45.9M	-7.66M	-14.84M	-13.7M	-10.84M
Operating CF Margin %	-1.57%	-0.24%	-0.57%	-	-
Operating CF Growth %	-	0.83%	-0.94%	0.08%	0.21%
Net Income	-37.23M	-45.74M	-27.55M	18.69M	-17.43M
Depreciation & Amortization	2.13M	2.37M	0	0	0
Stock-Based Compensation	0	0	427K	603K	830K
Deferred Taxes	164K	0	0	0	0
Other Non-Cash Items	5.42M	5.18M	10.66M	-29.85M	5.96M
Working Capital Changes	-16.38M	30.52M	1.62M	-3.15M	-193K
Change in Receivables	5.34M	-1.81M	0	0	-1.98M
Change in Inventory	0	0	0	0	0
Change in Payables	-4.35M	7.05M	1.98M	-2.25M	2.24M
Cash from Investing+	39.21M	-949K	0	0	0
Capital Expenditures	-2.73M	-949K	0	0	0
CapEx % of Revenue	0.09%	0.03%	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	10.12M	59.13M	9.57M	5M	87.09M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	0	34K	5M	8.65M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-48.62M	-8.61M	-14.84M	-13.7M	-10.84M
FCF Margin %	-1.66%	-0.27%	-0.57%	-	-
FCF Growth %	-	0.82%	-0.72%	0.08%	0.21%
FCF per Share	-71.40	-10.67	-15.95	-10.81	-4.87
FCF Conversion (FCF/Net Income)	1.23x	0.17x	0.45x	-0.73x	0.62x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-119.99%	-111.85%	-241.3%	-	-59.37%
Gross Margin	100%	92.46%	89.27%	-	-
Net Margin	-126.97%	-145.58%	-128.47%	-	-
Debt / Equity	0.55x	0.29x	-	-	-
Interest Coverage	-	-	-	-	-3.26x
FCF Conversion	1.23x	0.17x	0.45x	-0.73x	0.62x
Revenue Growth	-	7.14%	-17.56%	-100%	-

Frequently Asked Questions

Growth & Financials

Palvella Therapeutics, Inc. (PVLA) grew revenue by 0.0% over the past year. Growth has been modest.

Palvella Therapeutics, Inc. (PVLA) reported a net loss of $33.0M for fiscal year 2024.

Dividend & Returns

Palvella Therapeutics, Inc. (PVLA) has a return on equity (ROE) of -59.4%. Negative ROE indicates the company is unprofitable.

Palvella Therapeutics, Inc. (PVLA) had negative free cash flow of $17.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener